MBRX Metabasis Therapeutics Inc. featured news, full reports, and detailed charts
Metabasis Therapeutics Inc. (MBRX) Wrap Up:
Metabasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel drugs targeting the liver and liver pathways. Its product pipeline includes clinical-stage product candidates and advanced discovery programs for the treatment of metabolic diseases, such as diabetes and hyperlipidemia. The company?s product candidates under development comprise MB07811, which is in Phase II clinical trials for the treatment of hyperlipidemia; and MB07803, which is in Phase II clinical trials for the treatment of type 2 diabetes. Its metabolic disease advanced discovery programs consist of AMPK, a metabolic disease program focusing on the development of drug candidates for the treatment of type 2 diabetes and other metabolic diseases; Glucagon Antagonist, a program focusing on identifying orally bioavailable glucagon antagonists for the treatment of type 2 diabetes; and TRß agonist, a second-generation program to identify drug candidates for the treatment of hyperlipidemia. It has collaborative research and development agreements with Roche; Merck & Co.; Idenix Pharmaceuticals, Inc.; Daiichi Sankyo Company, Ltd.; Valeant Pharmaceuticals International; and Schering Corporation. The company was founded in 1997 and is based in La Jolla, California.Metabasis Therapeutics Inc. (MBRX*(D):NASDAQ)
Snapshot of Metabasis Therapeutics Inc. (MBRX)
|
OPEN
$0.39
|
PREVIOUS CLOSE
$0.40
|
|
|
DAY HIGH
$0.40
|
DAY LOW
$0.38
|
|
|
52 WEEK HIGH
06/8/09 - $1.15
|
52 WEEK LOW
05/27/09 - $0.21
|
|
|
MARKET CAP
13.9M
|
AVERAGE VOLUME 3 mo
259.3K
|
|
|
DILUTED EPS TTM
$-0.35
|
SHARES OUTSTANDING
35.2M
|
|
|
MBRX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
MBRX Top Compensated Officers
Executives, Board Directors
Key developments for Metabasis Therapeutics Inc. (MBRX)
Metabasis Therapeutics Inc. expected to Report Fiscal Year 2009 Results on March 29, 2010. This event was calculated by Capital IQ (Created on November 13, 2009).
Metabasis Therapeutics Inc. expected to Report Q3 2009 Results on November 30, 2009. This event was calculated by Capital IQ (Created on November 11, 2009).
Metabasis Therapeutics Inc. discontinued Edgardo Baracchini, Ph.D., M.B.A.'s employment as Metabasis' Senior Vice President of Business Development, effective October 23, 2009. On October 26, 2009, the Board appointed David F. Hale, its current Executive Chairman, to serve as Acting Principal Executive Officer effective as of October 30, 2009 and contingent upon the previously announced departure of Mark D. Erion, Ph.D., Metabasis' current President, Chief Executive Officer and Chief Scientific Officer. On October 26, 2009, the Board appointed Tran B. Nguyen, M.B.A., its current Vice President of Finance, Chief Financial Officer, Secretary and Treasurer, to serve as Principal Accounting Officer effective as of October 26, 2009.
MBRX Competitors
| Company | Last | Change |
| Karo Bio AB | kr5.30 SEK | -0.05 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | MBRX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.0x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.5x |
|
|
MBRX |
||
MBRX transactions
| Type Date |
Target |
|
Merger/Acquisition
October 26, 2009 |
-- |